07:09 EDT Insmed (INSM) backs FY25 global ARIKAYCE revenue view $405M-$425M
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- INSM Upcoming Earnings Report: What to Expect?
- Insmed says NEJM publishes ‘positive’ results from Phase 3 ASPEN study
- Insmed’s Brensocatib: A Promising Solution for Bronchiectasis in AATD Patients
- Insmed’s Strategic Positioning and Growth Potential Justify Buy Rating Despite Leadership Change
- Insmed’s Chief Commercial Officer Resigns for Personal Reasons
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue